Zhoujie Ye

Dr. Zhoujie Ye


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2024 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
YCYujia Chen
Yujia Chen
ZYZhoujie Ye
Zhoujie Ye
MLMeijia Lin
Meijia Lin
LZLiping Zhu
Liping Zhu
LXLiangpu Xu
Liangpu Xu
XWXin-Rui Wang
Xin-Rui Wang

18 October 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
XWXinrui Wang
Xinrui Wang
MLMeijia Lin
Meijia Lin
LZLiping Zhu
Liping Zhu
ZYZhoujie Ye
Zhoujie Ye
Cyclic GMP-AMP synthetase (cGAS), recognized as the primary DNA sensor within cells, possesses the capability to identify foreign DNA molecules along with free DNA fragments. This identification process facilitates the production of type I IFNs through the activator of the interferon gene (STING) which induces the phosphorylation of downstream transcription factors. This action characterizes the most archetypal biological functionality of the cGAS-STING pathway. When treated with anti-tumor agents, cells experience DNA damage that triggers activation of the cGAS-STING pathway, culminating in the expression of type I IFNs and associated downstream interferon-stimulated genes. cGAS-STING is one of the important innate immune pathways,the role of type I IFNs in the articulation between innate immunity and T-cell antitumour immunity.type I IFNs promote the recruitment and activation of inflammatory cells (including NK cells) at the tumor site.Type I IFNs also can promote the activation and maturation of dendritic cel(DC), improve the antigen presentation of CD4+T lymphocytes, and enhance the cross-presentation of CD8+T lymphocytes to upregulating anti-tumor responses. This review discussed the cGAS-STING signaling and its mechanism and biological function in traditional tumor therapy and immunotherapy.

16 April 2025
Verified
Book Chapter
Open access
PDF file
ZYZhoujie Ye
Zhoujie Ye
HYHaile Yu
Haile Yu
LZLiping Zhu
Liping Zhu
XFXiaoLu Fan
XiaoLu Fan
ALAizhu Lin
Aizhu Lin
XWXin-Rui Wang
Xin-Rui Wang
Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor that plays a pivotal role in the development and progression of cancers, particularly in breast and gastric cancers. While HER2 overexpression is commonly attributed to gene amplification, recent studies indicate that epigenetic modifications, such as DNA methylation, histone modification, and non-coding RNA interference, are also critical in regulating HER2 expression and activity. This article will focus on the relationship between HER2 and epigenetic modification.

14 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYangkun Shen
Yangkun Shen
ZYZhoujie Ye
Zhoujie Ye
XZXiangqian Zhao
Xiangqian Zhao
ZFZhihua Feng
Zhihua Feng
JCJinfeng Chen
Jinfeng Chen
QCQi Chen
Qi Chen
Upon HSV-1 infection, viral protein 16 (VP16), supported by Host Cell Factor C1 (HCFC1), is rapidly transported into the nucleus, and help to express a series of HSV-1 immediate-early proteins to begin its lytic replication. However, no direct evidence has shown if the HCFC1 deficiency can affect the proliferation of HSV-1 so far. Here, we showed that the HCFC1 deficiency led to a strong resistance to HSV-1 infection. Moreover, we identified Host Cell Factor C1 Regulator 1 (HCFC1R1) as a new host factor acting early in HSV infection for the transport of the HSV-1 capsid to the nucleus. The HCFC1R1 deficiency also led to a strong resistance to HSV-1 infection. The HCFC1R1 deficiency did not affect the attachment of HSV-1 to host cells but act early in HSV-1 infection by perturbing the formation of HCFC1/VP16 complex. Remarkably, in addition to wild-type HSV-1 infection, the host cells in the absence of either HCFC1 or HCFC1R1 showed strong resistant to the infection of TK-deficient HSV-1, which strain can course severe symptoms and tolerate to the current anti-HSV drug Acyclovir. Our data suggest that HCFC1 or HCFC1R1 may be used as the novel target for developing anti-HSV-1 therapies. IMPORTANCE: Herpes simplex virus-1 (HSV-1) is widely spread in the human population and can cause a variety of herpetic diseases. Acyclovir, a guanosine analogue that targets the TK protein of HSV-1, is the first specific and selective anti-HSV-1 drug. However, the rapid emergence of resistant HSV-1 strains is occurring worldwide, endangering the efficacy of Acyclovir. Alternatively, targeting host factors is another strategy to stop HSV-1 infection. Unfortunately, although the HSV-1’s receptor, Nectin-1, was discovered in 1998, no effective antiviral drug to date has been developed by targeting Nectin-1. Targeting multiple pathways is the ultimate choice to prevent HSV-1 infection. Here we demonstrated that the deletion of HCFC1 or HCFC1R1 exhibits a strong inhibitory effect on both wild-type and TK-deficient HSV-1. Overall, we present evidence that HCFC1 or HCFC1R1 may be used as the novel target for developing anti-HSV-1 therapies with a defined mechanism of action.

23 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JHJinlong Huang
Jinlong Huang
LZLiping Zhu
Liping Zhu
WZWeiqing Zhang
Weiqing Zhang
DLDongliang Lin
Dongliang Lin
LLLuoyu Lian
Luoyu Lian
ZYZhoujie Ye
Zhoujie Ye
Lung squamous cell carcinoma (LUSC) is associated with limited therapeutic options and poor clinical prognosis. The Octamer nucleotide--binding transcription factor (NONO), which lacks the POU domain, is implicated in nearly every aspect of gene regulation. It participates in various biological processes including cell proliferation, apoptosis, migration, and DNA damage repair. In this study, we report elevated expression of the NONO gene in LUSC as identified through tumor databases. Our biological function experiments confirmed that NONO promotes the proliferation of LUSC cells by inhibiting apoptosis and enhances the tumor cells’ capabilities for invasion and metastasis. Through the mediation of the PI3K/AKT signaling pathway, NONO regulates downstream molecules such as FOXO1 and GSK3β, which are related to cell proliferation and apoptosis. It participates in the regulation of LUSC cell proliferation, invasion and metastasis, and can serve as a potential clinical target for LUSC, providing ideas for exploring new treatment methods.

1 January 2026 in BioMed Research International
Verified
Journal Article
Open access
LZLiping Zhu
Liping Zhu
XPXiaoyan Peng
Xiaoyan Peng
HYHaile Yu
Haile Yu
XFXiaolu Fan
Xiaolu Fan
ZYZhoujie Ye
Zhoujie Ye
Dysregulation of histone modifications contributes to the development of cancer. The loss of methylation on histone H3 and H4 and the loss of acetylation serve as indicators of tumors. Histone demethylase KDM3B, which contains a JmjC domain, plays an important role in tumorigenesis and development by removing H3K9me1/2 methylation. It also has a significant impact on regulating different types of cancer. KDM3B′s role in prognosis and tumor formation in cancer has not been thoroughly studied. In this study, we analyzed KDM3B expression data from the TCGA database in a pan‐cancer analysis. Our results show that KDM3B is highly expressed in many cancer types and is closely associated with poor prognosis. KDM3B expression is associated with immune checkpoint activities, lymphocyte infiltration, and immune landscape changes, suggesting that KDM3B could be a target for cancer therapy.